Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Poxel/Sumitomo Dainippon to Launch Twymeeg on Sept. 16
September 13, 2021
- Adcetris Filed for 1st-Line Pediatric Nod for Hodgkin’s Lymphoma
September 13, 2021
- Ayumi Can Make 2 Billion Calonal Tablets Annually, Cover Substitute Demand for Recalled Products: CEO
September 10, 2021
- Sumitomo Dainippon Predicts 20-30 Billion Yen Sales from “Frontier Business” by FY2027
September 10, 2021
- SymBio Starts Nonclinical Study of Brincidofovir IV for Brain Tumors
September 9, 2021
- Kyowa Kirin Bags Japan Rights to AM-Pharma’s SA-AKI Drug
September 9, 2021
- Opdivo/Yervoy Gets First-Line OK for Malignant Pleural Mesothelioma in Taiwan
September 9, 2021
- Mitsubishi Tanabe Launches Global PII Study for Spinal Cord Injury Drug
September 9, 2021
- Rohto, Osaka Univ., and AI Firm to Develop New Solution for Predicting Systemic Diseases from Fundus Data
September 9, 2021
- Shionogi Forms Capital Alliance with Robotic Startup to Develop New Solutions
September 9, 2021
- Drug Makers’ Detailing Activities Collectively Down in July: Intage
September 9, 2021
- Follow-On AGs Gaining Ground with 10 Launches in 2 Years, More Expected amid Generic Quality Concerns
September 9, 2021
- Aloxi Authorized Generic Now Available Ahead of Gx Contenders
September 8, 2021
- MSD Leading in Oral COVID-19 Drug Race in Japan, Trailed by Pfizer; Shionogi Top Domestic Player
September 8, 2021
- Post-Vaccination Death Cases Being Investigated with Integrity: Takeda
September 8, 2021
- Japan Ethical Drug Sales Down 0.5% in July: Crecon
September 8, 2021
- Nichi-Iko’s Medipal Tie-Up Stirring Concerns over Generic Trades, Price Gyrations
September 7, 2021
- Keytruda Top-Selling Drug in Japan in August: Encise
September 7, 2021
- Takeda Faces New Problem on Leuplin, System Glitch Cripples Supply of 1, 3-Month Products
September 7, 2021
- GSK Files COVID-19 Antibody Drug Sotrovimab in Japan
September 7, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…